Psilocybin’s acute and persistent brain effects: a precision imaging drug trial
Abstract Psilocybin (PSIL) is a psychedelic drug and a promising experimental therapeutic for many psychiatric conditions. Precision functional mapping (PFM) combines densely repeated resting state fMRI sampling and individual-specific network mapping to improve signal-to-noise ratio (SNR) and effec...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | Scientific Data |
| Online Access: | https://doi.org/10.1038/s41597-025-05189-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849328918743482368 |
|---|---|
| author | Subha Subramanian Travis Rick Reneau Demetrius Perry Ravi Chacko Timothy O. Laumann Karin Flavin Christine Horan Julie Schweiger Nicholas Metcalf Eric J. Lenze Abraham Z. Snyder Nico U. F. Dosenbach Ginger Nicol Joshua S. Siegel |
| author_facet | Subha Subramanian Travis Rick Reneau Demetrius Perry Ravi Chacko Timothy O. Laumann Karin Flavin Christine Horan Julie Schweiger Nicholas Metcalf Eric J. Lenze Abraham Z. Snyder Nico U. F. Dosenbach Ginger Nicol Joshua S. Siegel |
| author_sort | Subha Subramanian |
| collection | DOAJ |
| description | Abstract Psilocybin (PSIL) is a psychedelic drug and a promising experimental therapeutic for many psychiatric conditions. Precision functional mapping (PFM) combines densely repeated resting state fMRI sampling and individual-specific network mapping to improve signal-to-noise ratio (SNR) and effect size in brain imaging research. We present a randomized cross-over study in which PFM was used to characterize acute and persistent effects of psilocybin or methylphenidate (MTP) on brain networks. Seven healthy volunteers (mean age 34.1 years, SD = 9.8; n = 3 females, n = 6 Caucasians) underwent (1) extensive baseline imaging, (2) imaging beginning 60–90 minutes after drug exposure, and (3) longitudinal imaging for up to two weeks after drug exposure. Four individuals also participated in an open-label PSIL replication protocol over 6 months later. This dataset includes resting state (using advanced high-resolution multi-echo fMRI), task fMRI, structural, and diffusion basis spectral imaging as well as assessments of subjective experience. We are releasing this unique dataset as a resource for neuroscientists to study the acute and persistent effects of PSIL and MTP on brain networks. |
| format | Article |
| id | doaj-art-6856142a4e324fc8bbb63cc5f4f230b1 |
| institution | Kabale University |
| issn | 2052-4463 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Data |
| spelling | doaj-art-6856142a4e324fc8bbb63cc5f4f230b12025-08-20T03:47:24ZengNature PortfolioScientific Data2052-44632025-06-0112111210.1038/s41597-025-05189-0Psilocybin’s acute and persistent brain effects: a precision imaging drug trialSubha Subramanian0Travis Rick Reneau1Demetrius Perry2Ravi Chacko3Timothy O. Laumann4Karin Flavin5Christine Horan6Julie Schweiger7Nicholas Metcalf8Eric J. Lenze9Abraham Z. Snyder10Nico U. F. Dosenbach11Ginger Nicol12Joshua S. Siegel13Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical SchoolDepartment of Psychiatry, Washington University School of Medicine in St. LouisDepartment of Psychiatry, Washington University School of Medicine in St. LouisDepartment of Emergency Medicine, Advocate Christ Medical CenterDepartment of Psychiatry, Washington University School of Medicine in St. LouisDepartment of Psychiatry, Washington University School of Medicine in St. LouisMiami VA Medical CenterDepartment of Psychiatry, Washington University School of Medicine in St. LouisDepartment of Neurology, Washington University School of MedicineDepartment of Psychiatry, Washington University School of Medicine in St. LouisDepartment of Neurology, Washington University School of MedicineDepartment of Neurology, Washington University School of MedicineDepartment of Psychiatry, Washington University School of Medicine in St. LouisDepartment of Psychiatry, NYU Langone Center for Psychedelic Medicine, NYU Grossman School of MedicineAbstract Psilocybin (PSIL) is a psychedelic drug and a promising experimental therapeutic for many psychiatric conditions. Precision functional mapping (PFM) combines densely repeated resting state fMRI sampling and individual-specific network mapping to improve signal-to-noise ratio (SNR) and effect size in brain imaging research. We present a randomized cross-over study in which PFM was used to characterize acute and persistent effects of psilocybin or methylphenidate (MTP) on brain networks. Seven healthy volunteers (mean age 34.1 years, SD = 9.8; n = 3 females, n = 6 Caucasians) underwent (1) extensive baseline imaging, (2) imaging beginning 60–90 minutes after drug exposure, and (3) longitudinal imaging for up to two weeks after drug exposure. Four individuals also participated in an open-label PSIL replication protocol over 6 months later. This dataset includes resting state (using advanced high-resolution multi-echo fMRI), task fMRI, structural, and diffusion basis spectral imaging as well as assessments of subjective experience. We are releasing this unique dataset as a resource for neuroscientists to study the acute and persistent effects of PSIL and MTP on brain networks.https://doi.org/10.1038/s41597-025-05189-0 |
| spellingShingle | Subha Subramanian Travis Rick Reneau Demetrius Perry Ravi Chacko Timothy O. Laumann Karin Flavin Christine Horan Julie Schweiger Nicholas Metcalf Eric J. Lenze Abraham Z. Snyder Nico U. F. Dosenbach Ginger Nicol Joshua S. Siegel Psilocybin’s acute and persistent brain effects: a precision imaging drug trial Scientific Data |
| title | Psilocybin’s acute and persistent brain effects: a precision imaging drug trial |
| title_full | Psilocybin’s acute and persistent brain effects: a precision imaging drug trial |
| title_fullStr | Psilocybin’s acute and persistent brain effects: a precision imaging drug trial |
| title_full_unstemmed | Psilocybin’s acute and persistent brain effects: a precision imaging drug trial |
| title_short | Psilocybin’s acute and persistent brain effects: a precision imaging drug trial |
| title_sort | psilocybin s acute and persistent brain effects a precision imaging drug trial |
| url | https://doi.org/10.1038/s41597-025-05189-0 |
| work_keys_str_mv | AT subhasubramanian psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT travisrickreneau psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT demetriusperry psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT ravichacko psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT timothyolaumann psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT karinflavin psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT christinehoran psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT julieschweiger psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT nicholasmetcalf psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT ericjlenze psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT abrahamzsnyder psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT nicoufdosenbach psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT gingernicol psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial AT joshuassiegel psilocybinsacuteandpersistentbraineffectsaprecisionimagingdrugtrial |